p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246
Study sponsor: Aprea Therapeutics
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2019-07-10Actual
Enrollment · participants36Actual
Source updated2025-03-17Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.